These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19959680)

  • 1. Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.
    O'Connor RJ; Cummings KM; Rees VW; Connolly GN; Norton KJ; Sweanor D; Parascandola M; Hatsukami DK; Shields PG
    Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3334-48. PubMed ID: 19959680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance of tobacco industry retail marketing activities of reduced harm products.
    Slater S; Giovino G; Chaloupka F
    Nicotine Tob Res; 2008 Jan; 10(1):187-93. PubMed ID: 18188759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Literature review and summary of perceptions, attitudes, beliefs, and marketing of potentially reduced exposure products: communication implications.
    Pederson LL; Nelson DE
    Nicotine Tob Res; 2007 May; 9(5):525-34. PubMed ID: 17454709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consumer awareness and attitudes related to new potential reduced-exposure tobacco product brands.
    Parascandola M; Augustson E; O'Connell ME; Marcus S
    Nicotine Tob Res; 2009 Jul; 11(7):886-95. PubMed ID: 19541949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Harm reduction strategy in tobacco control].
    Gorini G
    Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Findings and implications from a national study on potential reduced exposure products (PREPs).
    Hund LM; Farrelly MC; Allen JA; Chou RH; St Claire AW; Vallone DM; Healton CG
    Nicotine Tob Res; 2006 Dec; 8(6):791-7. PubMed ID: 17132527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring the tobacco use epidemic II: The agent: Current and emerging tobacco products.
    Stellman SD; Djordjevic MV
    Prev Med; 2009 Jan; 48(1 Suppl):S11-5. PubMed ID: 18848577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Socioeconomic, demographic and smoking-related correlates of the use of potentially reduced exposure to tobacco products in a national sample.
    Shaikh RA; Siahpush M; Singh GK
    Tob Control; 2014 Jul; 23(4):353-8. PubMed ID: 23291431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of current and recent former smokers associated with the use of new potential reduced-exposure tobacco products.
    Parascandola M; Augustson E; Rose A
    Nicotine Tob Res; 2009 Dec; 11(12):1431-8. PubMed ID: 19915081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.
    Gray JN; Breland AB; Weaver M; Eissenberg T
    Nicotine Tob Res; 2008 Sep; 10(9):1441-8. PubMed ID: 19023835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential reduction exposure products and FDA tobacco and regulation: a CNS call to action.
    Heath J; Andrews J; Balkstra CR
    Clin Nurse Spec; 2004; 18(1):40-8; quiz 49-50. PubMed ID: 15061445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smokers' responses to advertisements for regular and light cigarettes and potential reduced-exposure tobacco products.
    Hamilton WL; Norton Gd; Ouellette TK; Rhodes WM; Kling R; Connolly GN
    Nicotine Tob Res; 2004 Dec; 6 Suppl 3():S353-62. PubMed ID: 15799598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Potentially Reduced Exposure Tobacco Products Among American Indian Smokeless Tobacco Users: Associations With Cessation Behaviors and Cotinine Levels.
    Comiford AL; Rhoades DA; Dvorak JD; Ding K; Mehta T; Spicer P; Wagener T; Doescher MP
    Public Health Rep; 2020 Jan; 135(1):141-149. PubMed ID: 31835016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring the tobacco use epidemic V: The environment: factors that influence tobacco use.
    Farrelly MC
    Prev Med; 2009 Jan; 48(1 Suppl):S35-43. PubMed ID: 19022281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the tobacco use epidemic I. Overview: Optimizing measurement to facilitate change.
    Giovino GA; Biener L; Hartman AM; Marcus SE; Schooley MW; Pechacek TF; Vallone D
    Prev Med; 2009 Jan; 48(1 Suppl):S4-10. PubMed ID: 18809429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring the tobacco use epidemic III: The host: data sources and methodological challenges.
    Delnevo CD; Bauer UE
    Prev Med; 2009 Jan; 48(1 Suppl):S16-23. PubMed ID: 18851990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods to assess potential reduced exposure products.
    Hatsukami DK; Giovino GA; Eissenberg T; Clark PI; Lawrence D; Leischow S
    Nicotine Tob Res; 2005 Dec; 7(6):827-44. PubMed ID: 16298718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating oral noncombustible potential-reduced exposure products for smokers.
    Blank MD; Eissenberg T
    Nicotine Tob Res; 2010 Apr; 12(4):336-43. PubMed ID: 20159791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to Reduce Illicit Trade of Regular Nicotine Tobacco Products After Introduction of a Low-Nicotine Tobacco Product Standard.
    Ribisl KM; Hatsukami DK; Huang J; Williams RS; Donny EC
    Am J Public Health; 2019 Jul; 109(7):1007-1014. PubMed ID: 31166743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the use of Global Youth Tobacco Survey (GYTS) data for developing evidence-based tobacco control policies in Turkey.
    Erguder T; Cakir B; Aslan D; Warren CW; Jones NR; Asma S
    BMC Public Health; 2008 Dec; 8 Suppl 1(Suppl 1):S4. PubMed ID: 19091047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.